Lupin has launched Sevelamer Hydrochloride tablets (800 mg) in the US market to treat hyperphosphatemia in patients with chronic kidney disease. After receiving approval from the US Food and Drug Administration, the company launched the product (USFDA).

Lupin announced on Tuesday that it has launched Sevelamer Hydrochloride tablets (800 mg) in the US market to treat hyperphosphatemia in patients with chronic kidney disease. After receiving approval from the US Food and Drug Administration, the company launched the product (USFDA). Lupin said in a statement that the medication will be manufactured at the company’s manufacturing facility in Nagpur. Hyperphosphatemia is defined as excessively high serum phosphate levels.

Sevelamer Hydrochloride tablets (800 mg) had an estimated annual sales of $75 million in the United States, according to IQVIA MAT December 2021 data.